Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: A population-based case-control study

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 4, 2009, Pages 269-275

  Myles, Puja R ^a   Hubbard, Richard B ^a   McKeever, Tricia M ^a   Pogson, Zara ^a   Smith, Christopher J P ^a   Gibson, Jack E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

ACE inhibitors; Case control; Epidemiology; Gastric acid suppressants; Pneumonia; Statins

Indexed keywords

ANTACID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; PROTON PUMP INHIBITOR; STEROID;

ADULT; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EXPOSURE; DRUG USE; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; UNITED KINGDOM; CASE CONTROL STUDY; COMMUNICABLE DISEASE; COMORBIDITY; HEALTH SURVEY; MEDICAL RECORD; MIDDLE AGED; PNEUMONIA; RISK; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTACIDS; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; FEMALE; GREAT BRITAIN; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; ODDS RATIO; PNEUMONIA; POPULATION SURVEILLANCE; PROTON PUMP INHIBITORS; RISK ASSESSMENT; RISK FACTORS;

EID: 65449189768     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1715     Document Type: Article

References (30)

1. Laheij R, Van Ijzendoorn M, Janssen M, Jansen J. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003; 18(8): 847-851.
2. Laheij R, Sturkenboom M, Hassings R, Dieleman J, Stricker B, Jansen J. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292(16): 1955-1960.
3. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117: 817-820.
4. Sarkar M, Hennessy S, Yang Y. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149: 391-398.
5. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia. Arch Intern Med 2007; 167: 950-955.
6. Schleinger RG, Fedson DS, Jick SS, Jick H, Meier C. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007; 27(3): 325-332.
7. van de Garde EMW, Hak E, Souverein PC, Hoes AW, van den Bosch JMM, Leufkens HGM. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006; 61: 957-961.
8. Ohkubo T, Chapman N, Neal B, Woodward M, Omae T, Chalmers J. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004; 169(9): 1041-1045.
9. Okaishi K, Morimoto S, Fukuo K, Niinobu T, Hata S, Onishi T. Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. Am J Hypertens 1999; 12(8 Pt 1): 778-783.
10. Takahashi T, Morimoto S, Okaishi K, et al. Reduction of pneumonia risk by an Angiotensin I-Converting Inhibitor in elderly Japanese inpatients according to insertion/deletion polymorphism of the Angiotensin I-Converting Enzyme Gene. Am J Hypertens 2005; 18: 1353-1359.
11. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalised with community-acquired pneumonia. BMC Pulmonary Med 2005; 5: 12. DOI:10.1186/1471-2466-5-12. (available online: http://www.biomedcentral.com/1471-2466/5/12).
12. Rafailidis PI, Matthaiou DK, Varbobitis I, Falagas ME. Use of ACE inhibitors and risk of community-acquired pneumonia: a review. Eur J Clin Pharmacol 2008; 64: 565-573.
13. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based perspective. Br Med J 2006; 333(7576): 999.
14. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Informat Prim Care 2004; 12: 171-177.
15. MacIntyre CR, McIntyre S, Cagney M. Community-based estimates of incidence and risk factors for childhood pneumonia in Western Sidney. Epidemiol Infect 2003; 131: 1091-1096.
16. Farr BM, Woodhead M, Macfarlane JT, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med 2000; 94: 422-427.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Disease 1987; 40(5): 373-383.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45(6): 613-619.
19. Adams J, Ryan V, White M. How accurate are Townsend Deprivation scores as predictors of self-reported health? A comparison with individual level data. J Publ Health 2004; 2004: (Nov): 1-6.
20. Morris R, Carstairs V. Which deprivation? A comparison of selected deprivation indexes. J Publ Health Med 1991; 13(4): 318-326.
21. Macfarlane J, Colville A, Guion A, Macfarlane R, Rose D. Prospective study of aetiology and outcome of adult lower-respiratory tract infections in the community. Lancet 1993; 341: 511-514.
22. Woodhead M, Macfarlane J, McCracken J, Rose D, Finch R. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 1(8534): 671-674.
23. Macfarlane J, Holmes W, Gard P, Macfarlane R, Rose D. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001; 56(2): 109-114.
24. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000; 29: 891-898. DOI: 10.1093/ije/29.5.891.
25. Rang HP. Rang and Dale's Pharmacology, 6th ed. Churchill Livingstone Elsevier: Philadelphia, 2007.
26. Myles PR, McKeever T, Hoare Z, Smith C, Hubbard R. The incidence of pneumonia in the United Kingdom: data from a computerized general practice database. Epidemiol Infect 2008.
27. BTS. British Thoracic Society Guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56 (suppl 4): 1-64.
28. NICE. Technology appraisal 94: Statins for the prevention of cardiovascular events. 2006.
29. DH. Coronary heart disease: national service framework for coronary heart disease- modern standards and service models. DH (ed). 2000.
30. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2007; 61: 774-785.